evidence table
Ribose Exercise Performance Randomized Trial Evidence Table
Structured evidence table for Ribose Exercise Performance Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Ribose Exercise Performance Randomized Trial | 32 40 34 The geroscience hypothesis holds that because aging is the primary risk factor for most chronic diseases, biological aging processes are the common upstream cause of disparate downstream diseases. | 3 | Peng Li-Ning (2026) | Beyond disease treatment and prevention: From geroscience and molecular hallmarks to gerotherapeutics and precision geromedicine |
| Ribose Exercise Performance Randomized Trial | Key examples: AMPK, sirtuins (SIRT1–7), FOXO factors, p53, autophagy regulators 5 6 López-Otín et alKroemer et al Gerozymes Enzymes whose age-associated overaccumulation degrades endogenous regenerative signaling molecules, suppressing tissue homeostasis. | 3 | Peng Li-Ning (2026) | Beyond disease treatment and prevention: From geroscience and molecular hallmarks to gerotherapeutics and precision geromedicine |
| Ribose Exercise Performance Randomized Trial | Decline in IC is codified in ICD-11 as Ageing-Associated Decline in IC (code MG2A) 19 30 WHO ICOPERabheru et al Senility Old Age Ageing-Associated Decline in Intrinsic Capacity 29 30 , ICD-10 carried code R54—a term increasingly abandoned in clinical practice due to its pejorative connotations. | 3 | Peng Li-Ning (2026) | Beyond disease treatment and prevention: From geroscience and molecular hallmarks to gerotherapeutics and precision geromedicine |
| Ribose Exercise Performance Randomized Trial | 1 2 1 1 1 By 2050, more than two billion individuals worldwide will be aged 60 years or older, with super-aged societies—defined as nations where more than 20% of the population exceeds 65 years—proliferating across East Asia, Europe, and North America.Taiwan reached super-aged status in 2025, compressing a demographic transition that took Western nations several decades into a single generation. | 3 | Peng Li-Ning (2026) | Beyond disease treatment and prevention: From geroscience and molecular hallmarks to gerotherapeutics and precision geromedicine |
| Ribose Exercise Performance Randomized Trial | Objective Weight loss in older men with obesity and hypogonadism accelerates musculoskeletal decline, yet the underlying metabolic mechanisms remain unclear. | 4 | Viola V (2026) | Testosterone plus lifestyle therapy improves skeletal muscle glycolysis in older men with obesity and hypogonadism. |
| Ribose Exercise Performance Randomized Trial | Testosterone replacement therapy (TRT), when added to lifestyle therapy (LT), mitigates this decline, but its metabolic basis has not been defined. | 4 | Viola V (2026) | Testosterone plus lifestyle therapy improves skeletal muscle glycolysis in older men with obesity and hypogonadism. |
Source documents